COMMUNICATED: Seegene and Springer Nature announce the winners of the Open Innovation Program

(Information sent by the signatory company).

COMMUNICATED: Seegene and Springer Nature announce the winners of the Open Innovation Program

(Information sent by the signatory company)

SEOUL, South Korea, March 21, 2024 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, and Springer Nature, a leading global community service provider of research, announced the final list of participants for the diagnostic reagent development project on March 15, 2024 (GMT), through the online platform of the Open Innovation Program ( /open-innovation/2023-2024-announcements/).

In September 2023, Seegene and Springer Nature opened applications to scientists and experts from across the global community for the 15 projects designated to develop Seegene syndromic qPCR diagnostic reagents for the Open Innovation Program.

During the initial document selection stage, a total of 281 applications from 47 different countries were submitted, demonstrating global interest in the program. Two rounds of evaluations were carried out, which included documentary evaluation and country-specific on-site evaluations. After a rigorous evaluation process, a total of 26 applications were selected. The total number of awardees selected is 17, including those who applied for more than one project.

The selected projects and the final number of winners are as follows:

The Open Innovation Program awarded the prizes to a total of 12 countries with the following distribution: Belgium (3), Netherlands (1), Germany (2), Italy (3), Portugal (1), Canada (3), United States United States (3), Mexico (2), Argentina (1), United Arab Emirates (3), South Korea (3) and Kenya (1). (The figures in parentheses indicate the number of selected projects).

Awardees will receive research grants of up to $600,000 per project. In addition, Seegene will provide syndromic qPCR reagents, extraction reagents, development system (SGDDS), test instrument (AIOS) and related software free of charge throughout the collaboration period.

Developing products that bring together the knowledge and experience of scientists around the world is essential to achieving the overall vision: 'A disease-free world'. The inaugural Open Innovation Program marks the beginning of this effort.

"The candidates' excellent capabilities and great diversity present a valuable opportunity to cultivate a strong global network of clinical trial collaborations," said Dr. Jik Young Park, Director of Development Automation at Seegene. Dr. Park was a member of the panel responsible for reviewing the submitted applications.

The Open Innovation Program is an integral part of Seegene's broader technology sharing initiative, SG OneSystem™ business, which launched in 2023 and aligns with the company's vision of realizing a "disease-free world" .

SG OneSystem™ business involves the dissemination of Seegene's extensive experience and knowledge accumulated over 20 years. The initiative includes collaborating with representative institutions of each country, to effectively develop diagnostic products adapted to the needs of the local market.

Pursuing this vision, Seegene has further strengthened its SG OneSystem™ business through strategic collaboration with Microsoft in January 2024, marking an important milestone in its commitment to advancing global healthcare solutions. Seegene's Digitized Development System (SGDDS), which allows less experienced researchers to develop trials, will integrate Microsoft Azure services, including the Azure OpenAI service.

About Seegene

Seegene has 23 years of dedicated R&D, manufacturing and business experience around syndromic quantitative PCR technologies, highlighted during the COVID-19 pandemic when it provided more than 340 million COVID-19 tests to more than 100 countries worldwide. the world. The key feature of Seegene's unique syndromic PCR technologies is the ability to simultaneously identify 14 pathogens causing similar symptoms in a single tube and provide quantitative information on the infectivity profile to correlate with disease severity.

Photo - -

View original content: